fiercebiotech.com

DNS Records

Cloudflare

Content Delivery Network

Marketo

Customer Relationship Management

Google Webmaster Tools

Analytics

Bootstrap

Web Framework

Tailwind CSS

Web Framework

Vimeo

Videos

Twitter

Social Media

Facebook

Social Media

RSS

Open Web

Services

fiercebiotech

Twitter

fiercebiotech

Facebook

Social media

JSON+LD

{
  "@context": "https://schema.org/",
  "@type": "ItemList",
  "url": "https://www.fiercebiotech.com/fierce-biotech-homepage",
  "numberOfItems": 10,
  "itemListElement": [
    {
      "@type": "ListItem",
      "position": 1,
      "item": {
        "@type": "Article",
        "url": "https://ftp.mass-west.com/research/nih-announces-new-office-lead-shift-away-animal-testing-biomedical-research",
        "name": "NIH creates new office to lead shift away from animal testing",
        "description": "The Office of Research Innovation, Validation and Application (ORIVA) will focus on advancing techniques like organoids and computational models.",
        "image": "https://qtxasset.com/quartz/qcloud5/media/image/GettyImages-959758818.jpg?VersionId=qMNKxA9jSBcs1GERAPmNnAPCzHCpdiSV"
      }
    },
    {
      "@type": "ListItem",
      "position": 2,
      "item": {
        "@type": "Article",
        "url": "https://ftp.virtualtrialsconference.com/cro/bulgarian-cro-comac-medical-taps-new-ceo-eyes-global-expansion",
        "name": "CRO Comac Medical taps new CEO amid global expansion",
        "description": "Chris Smyth, Ph.D., is leaving his post as president of Icon Biotech to take the helm at Comac Medical in September.",
        "image": "https://qtxasset.com/quartz/qcloud5/media/image/GettyImages-1172807596.jpg?VersionId=L5ngLJM94.xLvHYBK1pAjNFyYw1qKo9c"
      }
    },
    {
      "@type": "ListItem",
      "position": 3,
      "item": {
        "@type": "Article",
        "url": "http://ftp.prcmidwest.com/biotech/immunic-multiple-sclerosis-asset-misses-primary-endpoint-ph-2-trial-company-points-positive",
        "name": "Immunic CEO says 'nobody should care at all' about missed primary endpoint in MS study",
        "description": "IMU-838 showed only “modest benefit” over placebo at improving the yearly rate of percent brain volume change in patients with progressive MS.",
        "image": "https://qtxasset.com/quartz/qcloud5/media/image/GettyImages-1185122593%20%282%29.jpg?VersionId=NDdAd82Ym_jhcZimBKWhfCzktTjZZNiS"
      }
    },
    {
      "@type": "ListItem",
      "position": 4,
      "item": {
        "@type": "Article",
        "url": "https://ftp.mass-west.com/biotech/biopharma-vc-financing-fell-20-q1-compared-24-globaldata",
        "name": "Biopharma VC financing fell 20% in Q1 compared to ’24: GlobalData",
        "description": "Biopharma venture funding dropped 20% in the first quarter of 2025 compared to the same period the year before, according to GlobalData.",
        "image": "https://qtxasset.com/quartz/qcloud5/media/image/GettyImages-1212115753.jpg?VersionId=wyUX0MRT8leEWrUh_1y.67zcMR3n88sG"
      }
    },
    {
      "@type": "ListItem",
      "position": 5,
      "item": {
        "@type": "Article",
        "url": "https://www.fiercebiotech.com/medtech/tariffs-push-ge-healthcare-cut-2025-guidance-despite-strong-quarterly-sales",
        "name": "Tariffs push GE HealthCare to cut 2025 guidance, despite strong quarterly sales",
        "description": "GE HealthCare said that while sales are predicted to stay the same, it now expects shrinking profit margins and earnings, and less cash on hand.",
        "image": "https://qtxasset.com/quartz/qcloud5/media/image/Signa%20Magnus.jpg?VersionId=ow7j60LU9upQn25UdbpOB1ms_qiQDW.i"
      }
    },
    {
      "@type": "ListItem",
      "position": 6,
      "item": {
        "@type": "Article",
        "url": "https://www.fiercebiotech.com/biotech/cellectar-seeking-strategic-alternatives-sinking-stock",
        "name": "Cellectar is seeking strategic alternatives, sinking stock",
        "description": "Radiopharma biotech Cellectar is seeking strategic alternatives after attempting to partner off its sole clinical-stage asset this winter.",
        "image": "https://qtxasset.com/quartz/qcloud5/media/image/GettyImages-1454696622.jpg?VersionId=s9fPtUHAQOdUTaQZ6fDAQ3jVfPJFgc2b"
      }
    },
    {
      "@type": "ListItem",
      "position": 7,
      "item": {
        "@type": "Article",
        "url": "https://ftp.mass-west.com/biotech/investor-pressures-acelyrin-exit-alumis-merger-and-liquidate-slams-inexplicable-process",
        "name": "Investor pressures Acelyrin to exit Alumis merger and liquidate, slams ‘inexplicable’ process",
        "description": "Trium Capital set out its case for voting against a deal it argues is worse for shareholders than liquidating the biotech.",
        "image": "https://qtxasset.com/quartz/qcloud5/media/image/GettyImages-1372767222.jpg?VersionId=i0oGzheeK1Pm9q3Xtp7DyPV5U5SZdUqj"
      }
    },
    {
      "@type": "ListItem",
      "position": 8,
      "item": {
        "@type": "Article",
        "url": "https://www.fiercebiotech.com/biotech/novartis-pays-800m-buy-regulus-phase-3-ready-kidney-drug",
        "name": "Novartis pays $800M upfront to buy Regulus for phase 3-ready kidney drug",
        "description": "If approved, Regulus' farabursen will enter a market already served by Otsuka’s Jynarque.",
        "image": "https://qtxasset.com/quartz/qcloud5/media/image/GettyImages-1134270327.jpg?VersionId=CPFh1Nmt55XpyMoh9.GDDKCPnQAQWrFm"
      }
    },
    {
      "@type": "ListItem",
      "position": 9,
      "item": {
        "@type": "Article",
        "url": "https://ftp.mass-west.com/biotech/fda-misses-pdufa-date-stealths-ultra-rare-disease-candidate-delaying-approval-decision",
        "name": "UPDATE: FDA misses PDUFA date for Stealth’s ultra-rare disease candidate, delaying approval decision—again",
        "description": "An approval decision for Stealth’s ultra-rare disease candidate has been delayed—again. This time, the FDA hasn't set a new date.",
        "image": "https://qtxasset.com/quartz/qcloud5/media/image/GettyImages-1456307595.jpg?VersionId=Z.iDMHSIqoB9iVI40fs0FiuM2KIVXlSc"
      }
    },
    {
      "@type": "ListItem",
      "position": 10,
      "item": {
        "@type": "Article",
        "url": "https://www.fiercebiotech.com/medtech/verily-nets-147m-michael-j-fox-foundation-grant-personalized-parkinsons-data",
        "name": "Verily nets $14.7M Michael J. Fox Foundation grant for personalized Parkinson's data",
        "description": "The MJFF has worked with Verily to assemble public data exploring the relationships between Parkinson's, genetics, the immune system and metabolism.",
        "image": "https://qtxasset.com/quartz/qcloud5/media/image/Elderly.jpg?VersionId=2IUCE7nYbxyf3r5p8ytFKARTfbdaSpho"
      }
    }
  ]
}